SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Acadia Healthcare Company, Inc. (ACHC) has a negative trailing P/E of -2.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 17.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -45.28%, forward earnings yield 5.69%. PEG 2.66.
Criteria proven by this page:
- VALUE (10/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -2.2); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -45.28%); analyst consensus target implies downside from the current price ($19.82, 25.4%); PEG > 2.0 means the stock is expensive even after accounting for growth (PEG 2.66).
- Forward P/E 17.6 — analysts expect a return to profitability with estimated EPS of $1.51 for FY2026.
- PEG Ratio 2.66 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield -45.28% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 5.69% as earnings recover.
- Analyst consensus target $19.82 (-25.4% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 39/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
10/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ACHC
Valuation Multiples
P/E (TTM)-2.2
Forward P/E17.6
PEG Ratio2.66
Forward PEG2.66
P/B Ratio1.25
P/S Ratio0.75
EV/EBITDA-6.8
Per Share Data
EPS (TTM)$-12.19
Forward EPS (Est.)$1.51
Book Value / Share$23.67
Revenue / Share$36.63
FCF / Share$-4.86
Yields & Fair Value
Earnings Yield-45.28%
Forward Earnings Yield5.69%
Dividend Yield0.00%
SharesGrow IV$4.67 (-82.4%)
Analyst Target$19.82 (-25.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
461.8 |
-4.81 |
1.31 |
1.01 |
- |
| 2017 |
14.2 |
0.00 |
1.10 |
1.00 |
- |
| 2018 |
-12.8 |
0.07 |
0.96 |
0.74 |
- |
| 2019 |
26.7 |
-0.17 |
1.16 |
1.45 |
- |
| 2020 |
-6.6 |
0.01 |
2.33 |
2.11 |
- |
| 2021 |
28.3 |
-0.22 |
2.14 |
2.33 |
- |
| 2022 |
27.0 |
0.65 |
2.62 |
2.83 |
- |
| 2023 |
-326.4 |
3.03 |
2.54 |
2.41 |
- |
| 2024 |
14.2 |
-0.01 |
1.18 |
1.15 |
- |
| 2025 |
-1.2 |
0.00 |
0.66 |
0.39 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.07 |
$2.81B |
$6.14M |
0.2% |
| 2017 |
$2.30 |
$2.84B |
$199.84M |
7% |
| 2018 |
$-2.01 |
$3.01B |
$-175.75M |
-5.8% |
| 2019 |
$1.24 |
$3.11B |
$108.92M |
3.5% |
| 2020 |
$1.62 |
$2.09B |
$143.19M |
6.9% |
| 2021 |
$2.25 |
$2.31B |
$190.64M |
8.2% |
| 2022 |
$2.98 |
$2.61B |
$273.14M |
10.5% |
| 2023 |
$-0.24 |
$2.93B |
$-21.67M |
-0.7% |
| 2024 |
$2.78 |
$3.15B |
$255.61M |
8.1% |
| 2025 |
$-12.16 |
$3.31B |
$-1.1B |
-33.3% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.51 |
$1.46 – $1.58 |
$3.41B |
$3.39B – $3.45B |
7 |
| 2027 |
$1.72 |
$1.61 – $1.96 |
$3.61B |
$3.58B – $3.67B |
7 |
| 2028 |
$1.88 |
$1.84 – $1.92 |
$3.82B |
$3.82B – $3.82B |
2 |
| 2029 |
$1.83 |
$1.80 – $1.87 |
$4.2B |
$4.15B – $4.26B |
1 |
